Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

Laura Shawver has joined Silverback Therapeutics Inc. as president, CEO and a director. Shawver, who succeeds Peter Thompson, was president and CEO of Synthorx Inc. until its $2.5 billion takeout in January by Sanofi (Euronext:SAN; NASDAQ:SNY). Shawver also chairs Cleave Therapeutics Inc. and is a board member of The Clearity Foundation and Relay Therapeutics Inc.

Silverback raised $78.5 million in a March series B to bring its innate immunity-activating antitumor mAb into the clinic (see “Silverback raises $78.5M series B”)...